Clinical trials: Total Neoadjuvant Treatment
Multiple Myeloma
Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma
In this phase I trial, patients with multiple myeloma will receive standard high dose melphalan with autologous stem cell rescue. In addition the pre-transplant conditioning will include targeted total marrow irradiation (TMI).
- Trial name
- BMT-02 (NCT02043860)
- Testing
- Total Marrow Irradiation, Autologous Transplant, Melphalan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Illinois Chicago
Rectal Cancer Patients
Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer
Research Objective:To investigate the efficacy and safety of the "total neoadjuvant chemoradiotherapy combined with immunotherapy" regimen for the treatment of locally advanced rectal cancer with high-risk features for…
- Trial name
- TNT-Immunity (NCT07214142)
- Testing
- PD-1
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
Locally Advanced Rectal Adenocarcinoma
Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old
The primary objective of the NACRE-2 trial is to assess whether the addition of chemotherapy after short-course radiotherapy is more effective than short-course radiotherapy alone in elderly patients with locally advanced rectal…
- Trial name
- NACRE-2 (NCT07118800)
- Testing
- FOLFOX4s, Short Course Radiotherapy
- Volunteers
- 160 people
- Sponsor
- UNICANCER
Rectal Cancer
Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer
The purpose of this study is to evaluate the safety and clinical activity of combining DCSZ11 with radiation and capecitabine/oxaliplatin (CAPOX) for the neoadjuvant treatment of patients with mismatch repair proficient (pMMR)…
- Trial name
- NCT07580339
- Testing
- DCSZ11, Radiation, Capecitabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cholangiocarcinoma, Biliary Cancer
Neoadjuvant Therapy in Biliary Adenocarcinoma
Feasibility of neoadjuvant therapy in resectable biliary adenocarcinoma.
- Trial name
- NCT04480190
- Testing
- Gemcitabine, Cisplatin, Fluorouracil
- Where
- United States
- Sponsor
- Jordan Kharofa
Rectal Cancer, Pathological Complete Response
Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial
The purpose of this study was to evaluate the effect of concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX pre- a delayed TME compared with 6 cycles XELOX post- a Regular Timing TME in patients with…
- Conditions
- Rectal Cancer, Pathological Complete Response, Disease Free Survival
- Trial name
- EXPLORE (NCT03038256)
- Testing
- concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME, concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX
- Where
- 2 sites in China
- Volunteers
- 244 people
- Sponsor
- Peking University People's Hospital
Rectal Cancer, Rectal Cancer Stage II
ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer
This is a prospective observational study with three primary objectives: Objective 1: Evaluate the detection rate and changes in circulating tumor DNA (ctDNA) levels in blood samples from colorectal cancer patients before…
- Conditions
- Rectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III
- Trial name
- NCT06589388
- Where
- Vietnam
- Volunteers
- 100 people
- Sponsor
- Gene Solutions
Prostate Adenocarcinoma, Stage I Prostate Cancer
Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer
This phase II trial studies how well androgen deprivation therapy and vorinostat followed by radical prostatectomy works in treating patients with prostate cancer that has not spread to other parts of the body.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- TARGET (NCT00589472)
- Testing
- Bicalutamide, Goserelin Acetate, Laboratory Biomarker Analysis
- Where
- 15 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Rectal Cancer
Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer
Phase II clinical trial, open-label, randomized, two arms, multicentre (possibly multinational). Academic, investigator initiated.
- Trial name
- AXEBEAM (NCT00828672)
- Testing
- Oxaliplatin, Bevacizumab, Capecitabine
- Where
- 9 sites in Belgium
- Volunteers
- 84 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Locally Advanced Rectal Cancer
TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer
This trial is a multicenter randomized Phase III study to verify the superiority of short-course preoperative radiation (SCRT) and CAPOXIRI over SCRT and CAPOX as preoperative treatments for locally advanced rectal cancer.
- Trial name
- ENSEMBLE (NCT05646511)
- Testing
- SCRT, CAPOX, CAPOXIRI
- Where
- 34 sites in Japan
- Volunteers
- 608 people
- Sponsor
- National Cancer Center Hospital East
Rectal Cancer
Total Neoadjuvant Treatment Combined With Adaptive Radiotherapy for Rectal Cancer
Diarrhea was the most frequently reported severe adverse event in the treatment regime of pre-operative sequential short-course radiotherapy followed by chemotherapy (so called total neo-adjuvant treatment).
- Trial name
- TNT-RECORD (NCT05883800)
- Testing
- On-couch adaptive radiotherapy
- Where
- Norway
- Volunteers
- 61 people
- Sponsor
- Haukeland University Hospital
Rectal Adenocarcinoma
Neoadjuvant Radiotherapy vs Upfront Surgery in Locally Advanced Proximal Rectal Cancer
The PRELUDE Study: A Prospective Cohort Study Comparing Neoadjuvant Radiotherapy Followed by Total Mesorectal Excision Versus Upfront Surgery in Patients with Locally Advanced Proximal Rectal Cancer The PRELUDE Study is a…
- Trial name
- PRELUDE (NCT07802197)
- Testing
- radiotherapy, surgery
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Istanbul University
Esophagus Cancer
Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer
Patients diagnosed with locally advanced esophageal squamous cell carcinoma (ESCC) that is deemed unresectable face a bleak prognosis.
- Trial name
- NEXUS-2 (NCT06430658)
- Testing
- Tislelizumab (BGB-A317) with chemoradiotherapy
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Rectal Cancer
Lumeneye Rectoscope for Assessment on Tumor Response After Total Neoadjuvant Treatment in Rectal Cancer
The objective of this prospective international cohort is to evaluate the LUMENEYE rectoscope for assessment on tumor response after total neoadjuvant treatment in rectal cancer.
- Trial name
- LUMEVAL (NCT06189846)
- Testing
- International Cohort
- Where
- 8 sites in France, Italy and 3 more
- Volunteers
- 82 people
- Sponsor
- Bordeaux Colorectal Institute Academy
Rectal Cancer
A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer
A Phase II Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer
- Trial name
- NCT04543695
- Testing
- Concurrent Chemoradiotherapy, XELOX, mFOLFOX
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Organ Preservation, Rectal Cancer Stage I
Total Neoadjuvant Therapy With Additional Consolidation Chemotherapy Followed by Local Excision Versus Total Neoadjuvant Therapy Followed by Local Excision at Stage I Rectal Cancer
Safety and Efficacy of Organ Preservation Treatment for Stage I Rectal Cancer: Optimization of Consolidation Chemotherapy Before Local Excision After Neoadjuvant Chemoradiotherapy (OPTION); A Multi-center, Prospective, Randomized…
- Conditions
- Organ Preservation, Rectal Cancer Stage I, Total Neoadjuvant Treatment, Consolidation Therapy
- Trial name
- OPTION (NCT07563907)
- Testing
- TNT with additional consolidation chemotherapy followed by local excision, TNT followed by local excision
- Where
- South Korea
- Volunteers
- 292 people
- Sponsor
- Seoul National University Hospital
Rectum Cancer
Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer
Aim: To investigate the safety and efficacy of organ preservation (OP) with watch-and-wait strategy (W\&W) or local excision (LE) in MRI stratified low-risk rectal cancer treated by total neoadjuvant treatment.
- Trial name
- BJCC-R01 (NCT04405206)
- Testing
- Oxaliplatin, Capecitabine, intensity modulated radiotherapy
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Peking University Cancer Hospital & Institute
Rectal Cancer
Total Neoadjuvant Therapy in Rectal Cancer Treatment
This is a randomized, controlled, parallel study to determine the efficiency and safety of total neoadjuvant therapy in rectal cancer treatment.
- Trial name
- NCT04747951
- Testing
- Concurrent Chemoradiotherapy, TME, consolidation chemotherapy
- Where
- Russia
- Volunteers
- 280 people
- Sponsor
- State Scientific Centre of Coloproctology, Russian Federation
Locally Advanced Low Rectal Adenocarcinoma, pMMR (Microsatellite Stable Rectal Cancer)
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer
The goal of this clinical trial is to find out if adding a PD-1 antibody (serplulimab) to FOLFOXIRI chemotherapy and radiotherapy works better than CAPOX chemotherapy with radiotherapy as total neoadjuvant therapy for adults with…
- Trial name
- NCT07277842
- Testing
- Serplulimab, FOLFOXIRI chemotherapy, CAPOX chemotherapy
- Where
- China
- Volunteers
- 382 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer
Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy
This is an open-label, multi-center, single-arm clinical study. All patients received 4-6 cycles total neoadjuvant therapy plus concurrent tislelizumab immunotherapy, then underwent clinical response assessment.
- Trial name
- TNTIT (NCT07561060)
- Testing
- Tislelizumab, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University